Cargando…

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

BACKGROUND: Recent studies showed inconsistent results of bevacizumab combined with chemotherapy vs single-agent therapy in terms of their safety and efficacy for the treatment of recurrent glioblastoma. Therefore, we performed a meta-analysis to explore the value of bevacizumab combined with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhouqing, Xu, Na, Zhao, Chongshun, Xue, Tao, Wu, Xin, Wang, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061394/ https://www.ncbi.nlm.nih.gov/pubmed/30087578 http://dx.doi.org/10.2147/CMAR.S173323

Ejemplares similares

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
por: Xu, Na, et al.
Publicado: (2018)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Comparative analysis on microsurgical removal of craniopharyngioma via lateral supraorbital approach and standard pterional approach
por: Zhao, Chongshun, et al.
Publicado: (2018)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma: A long-term retrospective study in Taiwan
por: Huang, Yu-Kai, et al.
Publicado: (2020)

Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials
por: Yang, Shou-Bo, et al.
Publicado: (2017)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
por: Fu, Minjie, et al.
Publicado: (2023)

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Omar, Ayman I.
Publicado: (2014)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
por: Beal, Kathryn, et al.
Publicado: (2011)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

RT-3 TREATMENT RESULTS OF AVAGAMMA THERAPY FOR RECURRENT GLIOBLASTOMA COMBINED WITH GAMMA KNIFE AND BEVACIZUMAB
por: Sato, Kenichi, et al.
Publicado: (2022)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
por: Nakayama, Yoshie, et al.
Publicado: (2013)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
por: Cardoso, Fatima, et al.
Publicado: (2009)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
por: Gleeson, Jack Patrick, et al.
Publicado: (2019)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis
por: YAMAGUCHI, Shigeru, et al.
Publicado: (2021)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
por: Laffaire, Julien, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lecjbmrnekbmohc18c8gh4urkm